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Abstract
Multidrug resistance (MDR) in model systems is known to be conferred by two different integral proteins, the 170-kDa P-
glycoprotein (Pgp) and the 190-kDa multidrug resistance-associated protein (MRP1). One possible pharmacological
approach to overcome drug resistance is the use of specific inhibitors, which enhance the cytotoxicity of known
antineoplastic agents. However, while many compounds have been proven to be very efficient in inhibiting Pgp activity only
some of them are able to inhibit MRP1. The other likely approach is based on the design and synthesis of new non-cross-
resistant drugs with physicochemical properties favoring the uptake of the drug by the resistant cells. The intracellular drug
retention influences its cytotoxic effect. The level of the intracellular drug content is a function of the amount of drug
transported inside the cell (influx) and the amount of drug expelled from the cell (efflux). In this work, the kinetics of drug
uptake and the kinetics of active efflux of several anthracycline derivatives in both Pgp expressing K562/Adr cells and MRP1
expressing GLC4/Adr cells was determined. Our data have shown that in both cell lines there is no correlation between the
resistance factor and the kinetics of drug efflux by these pumping systems. However, a very good correlation between the
resistance factor and the kinetics of drug uptake has been established in both cell lines: the resistance factor decreases when
the kinetics of drug uptake increases. This work has clearly shown that when the rate of transmembrane transport of
anthracycline is high enough, the efflux mediated by the protein transporter is not able to pace with it. The protein
transporter essentially operates in a futile cycle and the resistance factor is tending to one. It does not mean, however, that
when the resistance factor is close to one the anthracycline is not transported by the pump. ß 1999 Elsevier Science B.V.
All rights reserved.
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1. Introduction
Multidrug resistance (MDR) is a form of resist-
ance to natural product derived anticancer agents,
such as the anthracyclines, vinca alkaloids, and epi-
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podophyllotoxins, characterized by an increased
ATP-dependent e¥ux of the cytotoxic agent over
the cellular plasma membrane [1,2]. The multidrug
resistance described in the model systems is known
to consist of two di¡erent integral membrane pro-
teins, the 170-kDa P-glycoprotein (Pgp) and the
190-kDa multidrug resistance-associated protein
(MRP1) [3^6]. Both proteins belong to the superfam-
ily of the ATP binding cassette transport proteins or
tra⁄c ATPases [7], dependent on ATP hydrolysis for
the translocation of substrate across the membranes.
Clinical experience and laboratory studies have
demonstrated that most of the currently used natural
product anti cancer drugs are excellent substrates for
Pgp and/or MRP1. However, the pattern of drug
resistance shown by MRP1, while similar, is not iden-
tical to that of Pgp [8]. Overexpression of these trans-
porters by tumor cells is thought to be a signi¢cant
factor in both intrinsic and acquired resistance to
anticancer drugs. One pharmacological approach to
overcome the drug resistance is based on the use of
chemosensitizers enhancing the cytotoxicity of
known antineoplastic agents [9^11]. Although many
compounds were shown to be in inhibition of Pgp
activity [12], only few of them are active against
MRP1. The other approach to overcome the cell re-
sistance is the design and synthesis of new non-cross-
resistant drugs having physicochemical properties en-
hancing the uptake of the drug by the resistant cells
[13,14].
Cellular drug retention strongly in£uences its cy-
totoxicity and the level of intracellular drug content
is a function of the amount of drug transported in-
side the cell (in£ux) and the amount of drug expelled
out of cell (e¥ux). It has been suggested that the
ability of drug molecules to be recognized and trans-
ported by Pgp can be related to the degree of resist-
ance to these molecules and that compounds that are
poor substrates for Pgp are e⁄cient cytostatic agents
against MDR cells. In this paper we show that, at
least for anthracyclines, such reasoning cannot be
proven. We have determined the kinetics of uptake
and the kinetics of active e¥ux of several anthracy-
cline derivatives in both Pgp expressing K562/Adr
cells and MRP1 expressing GLC4/Adr cells. Our
data clearly show that in both cell lines there is no
correlation between the resistance factor and the ki-
netics of e¥ux of the drug by any of the two trans-
porters. However, a very good correlation between
the resistance factor and the kinetics of drug uptake
can be established in both cell lines: the resistance
factor decreases when the kinetics of drug uptake
increases. This work clearly indicates that when the
rate of transmembrane movement of anthracycline is
so high that pumping by the transporter cannot keep
pace with it, the transporter essentially operates in a
futile cycle and the resistance factor is tending to
one. It should be mentioned however, that the resist-
ance factor close to one does not indicate that the
anthracyclines are not transported by the protein
pumps.
2. Materials and methods
2.1. Cell culture and cytotoxicity assay
K562 leukemia cells and the P-glycoprotein ex-
pressing K562/ADR cells [15], as well as GLC4 and
the MRP expressing GLC4/ADR cells [16] were cul-
tured in RPMI 1640 (Sigma) medium supplemented
with 10% fetal calf serum (Bio media) at 37‡C in a
humidi¢ed incubator with 5% CO2. The resistant
K562/ADR and GLC4/ADR cells were cultured
with 400 nM or 1.2 WM DOX respectively until 1 to
4 weeks before experiments. Cell cultures used for
experiments were split 1:2 one day before use in
order to assure exponential growth.
The cytotoxicity of the anthracyclines was deter-
mined by incubating cells (105) with six di¡erent con-
centrations of anthracyclines for 72 h in standard six-
well plates. Then the IC50s (50% inhibitory drug con-
centrations) were determined by counting the cells
using a Coulter counter. The resistance factor (RF)
was de¢ned as the IC50 for the resistant cells divided
by the IC50 for the corresponding sensitive cells.
2.2. Drugs and chemicals
Daunorubicin (DNR) and pirarubicin (PIRA)
were provided by Roger Belon laboratory, doxorubi-
cin (DOX), idarubicin (IDA) by Pharmacia and Up-
john laboratory. WP697, WP608, WP656, WP742,
WP401 and WP715 were provided by Priebe [17].
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8-(S)-£uoroidarubicin (F-IDA) was provided by Me-
narini Recerche Sud, the group that originally syn-
thesized it [18] (Fig. 1). Stock solutions were pre-
pared in water just before use. Concentrations were
determined by diluting stock solutions in water to
approximately 10 WM and using O480 = 11 500 M31
cm31. Experiments were performed in HEPES/Na
bu¡er solutions containing 20 mM HEPES plus
132 mM NaCl, 3.5 mM KCl, 1 mM CaCl2 and 0.5
mM MgCl2, pH 7.3 in the presence of 10 mM so-
dium azide and either in the presence or the absence
of 5 mM glucose.
2.3. Determination of drug uptake and in£ux
coe⁄cient k+
Our experimental set up and its applicability to
measure the kinetics of uptake of anthracyclines by
the living cells has been extensively described and
discussed earlier [19^21]. It is based on a continuous
spectro£uorimetric monitoring of the decrease in the
£uorescence signal of anthracycline at 590 nm
(Vex = 480 nm) during incubation with cells in a
1 cm quartz cuvette. The decrease in £uorescence
occurring during the drug incubation with cells is
Fig. 1. Structures of the anthracyclines used.
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due to quenching of the £uorescence after inter-
calation of the anthracycline molecule between the
base pairs of DNA.
The £uorometric determination of the in£ux coef-
¢cient k, which determines the uptake kinetics of
anthracycline derivatives, includes the recording of
the £uorescence intensity F as a function of time t.
The obtained parameters are shown in Fig. 2. When
an anthracycline derivative is introduced into a sol-
ution containing cells (t = 0, concentration CT), the
£uorescence increases to Fo. The intercalation of the
drug between DNA bases causes the quenching of
£uorescence that results in the decrease of the £uo-
rescence signal. The drug di¡usion into the cell is
passive, so it obeys Fick’s law. The following equa-
tion has been previously established
dCet
dt
 3kCet  k3Cit 1
where Ce(t) and Ci(t) are the concentration of drug
in the extracellular medium and free in the cytosol
respectively. k and k3 are the passive in£ux and
e¥ux coe⁄cient, respectively.
When the extracellular and intracellular pH are the
same, it has been experimentally veri¢ed that the
passive e¥ux coe⁄cient k3 is equal to k.
At t = 0, Ce(t = 0) = CT and Ci(t = 0) = 0 and Eq. 1
becomes
dCet
dt
 
t0  3kCT:
Otherwise,
Ft
F0
 Cet
CT
D
dFt
dt
 
t0  3kWF0:
Thus, k is determined by the ratio between the ini-
tial slope dFt=dtt0 of the intensity curve and the
initial intensity (F0).
The main practical problem with this useful meth-
od is the precise determination of the initial data at
t = 0. It is usually not easy to measure precisely the
initial slope and the initial intensity because the dis-
tribution of the drug in the sample, just after its
addition, is not uniform. To eliminate such transient
problems, we used a method in which the initial data
can be obtained by extrapolation.
Thus, for sensitive cells,
dCet
dt
 3kCet  kCit
dCit
dt
 3kCit  kCet
8><>: 2
using
Cet  CTFtF0
Cit  CTFnF0
F03Ft
F03Fn
8><>: 3
where Fn is the signal intensity obtained for sensitive
cells at tCr.
Solving the di¡erential relations Eq. 2 and using
Fig. 2. Uptake of pirarubicin by drug-sensitive cells. F, the £uo-
rescence intensity at 590 nm (Vex = 480 nm) is recorded as a
function of time. Cells (2U106/ml) were suspended in a cuvette
¢lled with 2 ml bu¡er at pHe 7.3 and 37‡C under vigorous stir-
ring. At t = 0, 20 Wl of a stock anthracycline solution was added
to the cells, yielding an anthracycline concentration of CT = 1
WM; the £uorescence intensity was then F0. Once the steady
state was reached, the £uorescence intensity was FN, and the
overall concentration of drug intercalated between the base
pairs in the nucleus was Cn = CTW(F03Fn)/F0. The addition of
Triton X-100 yielded the equilibrium state. The £uorescence
was then FN, and the overall concentration of drug intercalated
between the base pairs CN = CTW(F03FN)/F0. Full line is the ex-
perimental record, the dotted line is the ¢tting of the experi-
mental curve obtained using Eq. 4 and F0 = 23.7, Fn = 11.4 and
k = 3.0U10312 l cells31 s31.
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Eq. 3, it comes
Ft  Fn  F03Fne
F0
F03Fn
k Wt
: 4
At the steady state, Fn can be determined directly
from the experimental curve (Fig. 2).
By tracing Ft3Fn=Fn in logarithmic scale, a
linear curve should then be obtained: where p is
the slope of this curve and Yo is the extrapolated
value of this curve at t = 0.
p  3 F0
F03Fn
k
Y 0  ln F03FnFn
 
8><>: 5
Consequently, Eq. 5 shows that F0 is given by Y0
and Fn, and k is deduced from p, F0 and Fn :
F0  Fn1 eY 0
k  3F03FnF0 p: 6
The value of k can then be calculated more accu-
rately using a personal computer.
To improve accuracy of these parameters, one can
¢t the experimental curve by the non-linear formula
Eq. 4 and using the previously calculated parameters
as initial values. Fig. 2 exhibits the ¢tting of the
experimental curve. The following values were ob-
tained: by calculation, F0 = 23.7, Fn = 11.4 and
k = 3.0U10312 l cells31 s31, and by ¢tting,
F0 = 25.8, Fn = 11.5 and k = 3.5U10312 l cells31 s31.
As we have already shown, the k of anthracy-
clines for resistant cells determined at t = 0 is the
same as that for sensitive cells [14,22]. In general,
however, the method described above is di⁄cult to
use for the uptake by resistant cells because of the
presence of the active drug e¥ux. Nevertheless, this
method may be used to determine the uptake by the
resistant cells deprived of energy by incubation in the
presence of 10 mM of N33 and the absence of glucose
[14]. We have checked that for all the compounds
studied here, the k value determined in energy-de-
prived resistant cells was the same as that found for
sensitive cells as well as that evaluated for resistant
cells with active transporter at t = 0.
2.4. Determination of the MRP1 or Pgp-mediated
e¥ux of anthracycline derivatives
Cells (1U106/ml; 2 ml per cuvette) are preincu-
bated for 30 min in HEPES bu¡er with sodium
azide, but without glucose. Depletion of ATP in
these cells was 90% as checked with the luciferin-
luciferase test [14,22]. The cells remained viable
throughout the experiment as checked with trypan
blue and calcein vital stain (data not shown). After
addition of anthracycline the decrease of the signal is
followed until steady state is reached. Since the pH
of the medium is chosen equal to the intracellular
pH, at steady state the extracellular free drug con-
centration (Ce) is equal to the cytosolic free drug
concentration (Ci). Then glucose is added, which
leads to restoration of control ATP levels within
2 min and increase of the £uorescence signal due to
the e¥ux of anthracycline. The ATP-dependent
anthracycline e¥ux is determined from the slope of
the tangent of the curve F = f(t), where F is the
£uorescence intensity at the time of addition of glu-
cose (Fig. 3). Since under these conditions at the
moment of adding glucose Ci = Ce, the passive in£ux
and e¥ux are equal and the net initial e¥ux repre-
sents the MRP1 or Pgp-mediated active e¥ux only.
In order to characterize the e¥ux, we have earlier
de¢ned a mean active e¥ux coe⁄cient (ka) [14,20,22]
according to the equation:
Va  kaWCi 7
ka is a good measure of VM/Km the ratio of the
maximum rate of e¥ux to the Michaelis constant.
2.5. Determination of pK values by potentiometric
measurements
The protonation constants of daunorubicin and
doxorubicin derivatives were calculated from pH ti-
tration data obtained at 37‡C using a Molspin auto-
matic titration system. Changes in pH were moni-
tored using a combined pH electrode (Russell
CMAW 757) calibrated for H activity. The relation-
ship between activity and concentration was calcu-
lated daily by titration with HNO3 [23]. The titra-
tions were performed with 0.1 M carbonate-free
NaOH. The ionic strength was adjusted to 0.1 with
KNO3, and drug concentration was ¢xed at 1033 M.
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The titrations were performed over the pH range
2.5^11.0 using a volume of 1.3 ml. The protonation
constants were calculated with the aid of a SUPER-
QUAD computer program [24].
3. Results
The structures of the 11 anthracycline derivatives
used in this study are shown in Fig. 1.
3.1. pK determination
The pK values obtained for these molecules are
collected in Table 1. Deprotonation of anthracycline
hydroxyl groups occurs in a very basic pH range
above 10 and therefore at pH 7.2 all remains un-
charged. The studied derivatives bear a single posi-
tive charge when protonated at the amino nitrogen
of the amino sugar moiety. In addition, the pK val-
ues of the amino groups were found to be in the
range between 6 and 9. Thus, the exact pK value
for each particular drug molecule will be the critical
parameter for the concentration of the neutral spe-
cies able to di¡use through the cell membrane at
experimental pH. The pK value of the amino sugar
nitrogen was most a¡ected by the adjacent substitu-
ents on a sugar ring. Because of the relatively broad
range of the pK values of the studied derivatives, the
concentrations of the neutral form of the drug
studied varies considerably. This allowed us to eval-
uate the impact of pK on the kinetics of uptake with-
in the large range of pK values. The concentration of
neutral form of the drug at experimental pH varied
from 4% to 95% (Table 1).
3.2. Kinetics of drug uptake by cells
The uptake of drugs by sensitive and energy-de-
pleted resistant cells was determined by continuous
monitoring of £uorescence decay of the drug as it
was incubated with the cells. In all experiments, the
intra- and extracellular pH was the same and equal
to 7.3. In each case, 106 cells/ml were incubated with
varying amounts of drug (1 to 10 WM). Fig. 2 shows
a typical decrease of £uorescence at 590 nm as a
Table 1
pK of anthracycline derivatives
Drug Number pK D0 %
DOX 1 8.4 7
WP697 2 8.2 11
DNR 3 8.4 7
WP608 4 7.8 24
WP656 5 8.7 4
F-IDA 6 8.4 7
PIRA 7 7.8 24
IDA 8 8.4 7
WP742 9 8.5 6
WP401 10 6.0 95
WP715 11 7.3 50
D0 stands for the molecule in the neutral form.
Fig. 3. Incorporation of daunorubicin (A) and WP401 (B) in
GLC4/Adr cells after depletion by incubation with azide and
determination of the active e¥ux rate (Va) after restoration of
ATP synthesis by the addition of glucose (normalized £uores-
cence intensity).
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function of time after the addition of pirarubicin to
sensitive K562 cells at pH 7.3. This type of curves was
used to calculate the in£ux coe⁄cients k as de-
scribed in Section 2. The in£ux coe⁄cients k are
collected in Tables 2 and 3 for K562/Adr and
GLC4/Adr cells respectively.
3.3. Kinetics of the Pgp- and MRP1-mediated e¥ux
of drug
The time required to reach the steady state of an-
thracycline accumulation in the energy-depleted cells
varied between 20 min (WP401 and PIRA) and 90
min (DNR). At this time point Ci = Ce was calcu-
lated from the (non-quenched) £uorescence (5, 6,
19) and Va was calculated as:
CT=F0WdF=dt
where F0 is the £uorescence of a CT WM anthracy-
cline solution and dF/dt the slope of the tangent to
the curve F(t) after addition of glucose which initi-
ated the active e¥ux component. Fig. 3 shows typi-
cal records obtained with DNR and WP401. The
same experiment was performed using the parent
cell lines, in which no active e¥ux could be detected
(not shown).
The mean active e¥ux coe⁄cients ka were calcu-
lated using Eq. 7 and are shown in Tables 2 and 3
for K562/Adr and GLC4/Adr cell line respectively.
3.4. Cell growth inhibition and resistance factors
The drug IC50 values obtained for sensitive cells
are collected in Tables 2 and 3, together with the
RF values for resistant cells. The most e¡ective,
IDA and PIRA, were about twice as cytotoxic as
DNR or DOX. In contrast, relative cytotoxicities
of the drugs towards the MDR cells were much dif-
ferent from those towards sensitive cells (see RF).
For example, IDA was 20 times more cytotoxic
than DOX.
3.5. Relation between RF, k+ and ka
The data in Figs. 4 and 5 clearly show that the
kinetics of uptake of the drugs vary over a very large
range. For instance, the kinetics of uptake of WP401
Table 3
Cross-resistance pattern of GLC4/Adr cells and kinetic parameters of anthracycline derivatives
Drug IC50(S) (nM) RF kU1012 l cells31 s31 kaU1012 l cells31 s31
DOX 11 þ 2 63 þ 10 0.03 þ 0.01 0.5 þ 0.1
DNR 12 þ 2 23 þ 4 0.31 þ 0.05 1.3 þ 0.2
WP656 9 þ 2 9 þ 2 5 þ 1 1.7 þ 0.2
PIRA 5 þ 1 5 þ 1 8 þ 2 1.4 þ 0.2
WP401 9 þ 2 3 þ 1 20 þ 3 1.5 þ 0.2
IC50(S) is the drug concentration required to inhibit 50% of sensitive cell growth.
Resistance factor (RF) value was calculated as resistant cell IC50/sensitive cell IC50. k and ka are the passive in£ux and active e¥ux
coe⁄cients respectively.
Data are mean þ standard deviation from three to ¢ve independent experiments on di¡erent days.
Table 2
Cross-resistance pattern of K562/Adr cells and kinetic parame-
ters of anthracycline derivatives
Drug IC50(S)
(nM)
RF kU1012 l
cells31 s31
kaU1012 l
cells31 s31
DOX 10 þ 2 32 þ 6 0.01 þ 0.002 0.3 þ 0.1
WP697 32 þ 4 21 þ 4 0.04 þ 0.004 1.9 þ 0.2
DNR 12 þ 3 18 þ 4 0.2 þ 0.02 1.5 þ 0.2
WP608 21 þ 4 15 þ 3 1.1 þ 0.1 1.9 þ 0.2
WP656 14 þ 3 7 þ 2 1.5 þ 0.2 2.6 þ 0.3
F-IDA 12 þ 3 6 þ 1 2.0 þ 0.2 2.0 þ 0.2
PIRA 4 þ 1 8 þ 2 3.5 þ 0.3 6.2 þ 1.1
IDA 6 þ 2 3 þ 1 4.0 þ 0.3 1.9 þ 0.2
WP742 33 þ 6 3 þ 1 4.0 þ 0.4 3.4 þ 0.4
WP401 12 þ 2 3 þ 1 7 þ 1 4.7 þ 0.5
WP715 11 þ 3 3 þ 1 13 þ 2 1.3 þ 0.2
IC50(S) is the drug concentration required to inhibit 50% of
sensitive cell growth.
Resistance factor (RF) value was calculated as resistant cell
IC50/sensitive cell IC50. k and ka are the passive in£ux and ac-
tive e¥ux coe⁄cients respectively.
Data are mean þ standard deviation from three to ¢ve inde-
pendent experiments on di¡erent days.
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is about 700 times higher than that of Dox in both
cell lines. In contrast, the drugs are extruded at com-
parable rates. The resistance factor strongly depends
on k and decreases as k increases. However there
is no correlation between the resistance factor and
the ability of the pumps, either Pgp or MRP1, to
e¥ux the drugs.
4. Discussion
The aim of this work was to dissect the resistance
factor in resistant cells, expressing either Pgp or
MRP1 transporter, into the relative contribution of
the kinetics of passive e¥ux and of active e¥ux of
anthracycline derivatives.
Fig. 5. Relation between the resistance factor (RF) and the passive in£ux coe⁄cient k. The values of RF have been plotted as a
function of log(k) for K562/ADR (left) and GLC4/ADR (right). The numbers indicate the nature of the anthracylines used according
to Table 1. The lines drawn have been least squares ¢tted to the data (RF =39.4 log(k)3102 for K562/Adr and RF =319.6
log(k)3210 for GLC4/Adr).
Fig. 4. Relation between the resistance factor (RF), the passive in£ux coe⁄cient k and the active e¥ux coe⁄cient ka for K562/ADR
(left) and GLC4/ADR (right).
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The resistance factor can merely be expressed as
the ratio of drug at the half-maximal inhibitory con-
centration (IC50) in the presence of a pumping sys-
tem, compared with the IC50 in its absence, i.e.
RF = Ce(R)/Ce(S). At the IC50, the internal drug con-
centrations should be the same in presence or ab-
sence of a pumping system (Ci(R) = Ci(S)) [25]. In
addition, for cells in the absence of pumping system
the external and internal drug concentration is the
same, i.e. Ce(S) = Ci(S). The resistance factor should
theoretically be given by the ratio of external to in-
ternal drug concentrations at the IC50 measured
when the pump is active, i.e. RF = Ce(R)/Ci(R). Tak-
ing into account that at steady state the kinetics of
in£ux is equal to the kinetics of e¥ux, i.e.
V = V3+Va and that the passive in£ux and e¥ux
coe⁄cients are equal (k = k3) it comes that RF
can be merely expressed as
RF  1 ka=k: 8
The data presented here clearly show the depend-
ency of RF on the kinetics parameters and essentially
on the kinetics of passive di¡usion. The RF values
calculated using relation Eq. 8 and those determined
experimentally are shown in Fig. 6. As a whole the
calculated values are lower than those determined
experimentally especially in the case of GLC4/Adr
cells. This result is not surprising as far as the used
equation implicitly assumes that (i) the cause of the
occurrence of MDR in these cells is the action of
transmembrane proteins that catalyze the active ex-
trusion of various compounds out of the cells, (ii) the
drug is not degraded during the three days of incu-
bation.
Concerning the second point, Beijnen et al. have
clearly recognized some years ago the instability of
anthracycline derivatives in cell culture media [26^
29]. From their data it can be estimated that in aque-
ous medium at pH 7.4, 37‡C and 0.1 M ionic
strength, after 3 days about 60% of doxorubicin
has undergone degradation. In addition, they have
observed that the 4P-congeners of doxorubicin, i.e.
4P-deoxydoxorubicin, 4P-0-methyl doxorubicin and
4P-epidoxorubicin all degrade with the same velocity.
We have shown that the same degradation product
(hereafter named D*) was observed with pirarubicin
[30]. Also we have demonstrated, in the case of doxo-
rubicin and pirarubicin [30], that the amount of
degraded molecule inside the cells was not the same
in sensitive and resistant one. Thus, when cells are
incubated for 3 days with pirarubicin, we have esti-
mated that in drug-sensitive cellsV100% of the drug
was present as the parent molecule but only V40%
in drug-resistant cells. When the cells are incubated
Fig. 6. Comparison of the experimental RF values and those calculated using the relation RF = 1+k/ka.
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under the same conditions with doxorubicin, V70%
of the drug are present as the parent molecule in
sensitive cells and only 20% in resistant cells. This
strongly suggests that (i) the drug degradation is
more important in the extracellular medium than in-
side the cells, (ii) due to the presence of active e¥ux
the time of residence of a drug inside the cell is high-
er in sensitive cells compared to resistant cells. Thus
a higher amount of degraded product is formed in
the presence of resistant cells than in the presence of
sensitive cells. This suggestion is supported by the
fact that in the case of sensitive cells, there is more
D* species accumulated inside the cells in the case of
doxorubin, which enters into the cells very slowly,
than in the case of pirarubicin which enters into
the cells V20 times more rapidly. Therefore it re-
sides a shorter time in the extracellular medium
than doxorubicin. Thus, the observed RF value is
higher than it could be expected when considering
kinetic data only. Taking into consideration the
oversimpli¢cation of the problem when calculating
RF using this equation we believe that the observa-
tion that RF calculated and RF measured have a
parallel behavior is already a good result.
The second important point is that according to
Eq. 8 RF should decrease as ka decreases and k
increases. However, the relative variation of ka for
the di¡erent drugs is low (V5) as compared to the
variation of k (V1000). Therefore, the impact of k
on the RF factor is by far more important than the
impact of ka. This is clearly shown in Fig. 4 which
shows that RF depends linearly on ln k and there-
fore can be expressed as a function of the lipophilic-
ity of the drug and of the pK of sugar amino func-
tion.
Clearly, our e¡orts to describe the kinetics of an-
thracycline transport in MDR tumor cell is an over-
simpli¢cation of what is actually going on in the cell.
This cell model should of course be regarded only as
a working model which is far from completion. How-
ever, this model makes possible to predict how mod-
i¢cations in the anthracycline molecule a¡ect its
transport characteristics and cell killing activity.
In the cancer cells the resistance mediated either by
Pgp or MRP1 can easily occur. The major clinical
challenge is then the overcoming of MDR without
a full knowledge of the type of pumping system
present. The use of chemosensitizers could be a fu-
ture solution however, both transporters are not sen-
sitive to the same molecules. Many compounds have
been proven to be very e⁄cient as inhibitors for Pgp
activity [12], however, only few of them are active
against MRP1. Thus, the discovery and clinical use
of chemosensitizing agents that would be e⁄cient
against both Pgp and MRP1 in the near future is
unlikely. In this context, the data presented here
showing that MDR mediated either by Pgp or
MRP1 can be overcome using drug exhibiting high
lipophilicity and/or low pK value, i.e. high kinetics of
uptake, could be promising for a very near future.
In conclusion, our results clearly establish that it is
false to a⁄rm that ‘the non-cross-resistant drugs are
not transported by Pgp’. The better e⁄ciency of lip-
ophilic anthracyclines is mainly due to their high
uptake rate and not to a decreased activity of Pgp
on MRP1 on these drug substrates.
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